Inventor
AARON P. YAMNIUK
Inventor
US
Overview
Patents· 9 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
C07Kprimary
C07KPeptides26%
A61KPreparations for medical, dental or toiletry purposes24%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%
C12NMicroorganisms or enzymes18%
G01NInvestigating or analysing materials by determining their chemical or physical properties9%
PatentTitleYear
11,952,420Nucleic acids encoding anti-TREM-1 antibodies202411,952,427Anti-CD40 antibodies and uses thereof202411,919,954Anti-TREM-1 antibodies and uses thereof202411,813,315Fibronectin based scaffold domain proteins that bind to myostatin202311,512,124Fibronectin type III domain proteins with enhanced solubility202211,352,440Antibodies against CD73 and uses thereof202211,306,149Anti-CD40 antibodies and uses thereof202211,213,586Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)202211,155,618Anti-TREM-1 antibodies and uses thereof2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021–2024Patents assigned to BRISTOL MYERS SQUIBB CO (9)· patent assignee history
2021–2024Based in US· patent location history
2022–2024Patents assigned to CYTOMX THERAPEUTICS INC (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| BRISTOL MYERS SQUIBB CO | 9 | 2021–2024 |
| CYTOMX THERAPEUTICS INC | 2 | 2022–2024 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 9 | 2021–2024 |